NCT03074513 2026-03-11
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
11 trialsNCT07332247 2026-02-04
PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC
Sun Yat-sen University
Phase 2 Recruiting
NCT03082534 2026-01-28
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
University of California, San Diego
Phase 2 Completed
NCT05807880 2026-01-23
ALTER-HN005
Sun Yat-sen University
Phase 2 Active not recruiting
NCT04004871 2025-12-11
Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal Carcinoma
Guangxi Medical University
Phase 2 Completed
NCT04925544 2025-10-21
Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies
Stanford University
Phase 2 Active not recruiting
NCT05305131 2025-09-23
Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer
National University Hospital, Singapore
Phase 2 Recruiting
NCT06688175 2025-08-07
IMRT Combined With Lobaplatin-based CCRT in Nasopharyngeal Carcinoma
The First Affiliated Hospital of Xiamen University
Phase 2 Enrolling by invitation
NCT06811844 2025-07-01
Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC
The First Affiliated Hospital of Xiamen University
Phase 2 Recruiting
NCT04875611 2025-04-24
NIVONASO-21
Maria Sklodowska-Curie National Research Institute of Oncology
Phase 2 Recruiting
NCT06892431 2025-03-25
JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer
Shanghai JMT-Bio Inc.
Phase 2 Not yet recruiting